Compare IRTC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | ACAD |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.6B |
| IPO Year | 2016 | 2004 |
| Metric | IRTC | ACAD |
|---|---|---|
| Price | $169.94 | $27.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 22 |
| Target Price | ★ $203.93 | $29.05 |
| AVG Volume (30 Days) | 454.2K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | N/A | ★ 1.54 |
| Revenue | $702,573,000.00 | ★ $1,047,118,000.00 |
| Revenue This Year | $27.20 | $15.16 |
| Revenue Next Year | $16.89 | $11.42 |
| P/E Ratio | ★ N/A | $17.62 |
| Revenue Growth | ★ 25.45 | 12.69 |
| 52 Week Low | $84.17 | $13.40 |
| 52 Week High | $212.00 | $27.73 |
| Indicator | IRTC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 69.78 |
| Support Level | $166.76 | $26.38 |
| Resistance Level | $187.98 | $27.73 |
| Average True Range (ATR) | 6.55 | 0.83 |
| MACD | -1.41 | 0.14 |
| Stochastic Oscillator | 9.08 | 88.00 |
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.